Neumora Therapeutics (NMRA) Return on Capital Employed (2023 - 2026)

Neumora Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 156.72% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 5059.0% year-over-year to 156.72% in Q1 2026; TTM through Mar 2026 was 156.72%, a 5059.0% decrease from a year earlier, with the FY2025 full-year figure at 108.85%, down 3890.0% from the prior year.
• Return on Capital Employed advanced to 156.72% in Q1 2026 per NMRA's latest filing, from 158.67% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 50.89% in Q4 2023 and bottomed at 158.67% in Q4 2025.
• The 4-year median for Return on Capital Employed is 98.42% (2024), against an average of 104.44%.
• Across the five-year window, Return on Capital Employed sank 3553 bps in 2024 and sank 7225 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 50.89% in 2023, then plunged by 70 bps to 86.42% in 2024, then plunged by 84 bps to 158.67% in 2025, then rose by 1 bps to 156.72% in 2026.
• Per Business Quant, the three latest NMRA Return on Capital Employed figures stand at 156.72% (Q1 2026), 158.67% (Q4 2025), and 140.35% (Q3 2025).